New research shows that blood markers, in connection with Alzheimer’s disease, signal a faster decrease in muscle strength in older adults, which emphasizes an opportunity for early detection and preventive interventions against age -related muscle loss.
Study: Blood biomarkers of Alzheimer’s disease and 12-year-old muscle strength processes in older adults in the community: a cohort study. Image Credit: TOA55/Shutterstock.com
A recent Lancet Healthy lifespan Study investigated the relationship between the biomarkers of Alzheimer’s disease (AD) and muscle strength.
The study suggests that early detection of Alzheimer’s Disease (AD) -related biomarkers is associated with progressive decrease in muscle strength and can help prevent sarcopenia via rapid interventions in older adults.
Sarcopenia and aging
Sarcopenia is a geriatric disorder that is characterized by a decrease in muscle strength and mass, which often occurs in aging. Previous studies have shown that, compared to muscle mass, muscle strength is a more accurate indicator for negative health results. That is why insight into the underlying causes of reducing muscle strength is crucial for the effective prevention of sarcopenia.
In addition to age -related metabolic and structural changes in muscles, skeletal muscle performance is also influenced by various chronic diseases, including cerebrovascular diseases, diabetes, cardiovascular diseases and respiratory diseases. The muscle performance of an individual is also linked to lifestyle factors, as well as biological and psychosocial parameters. Compared to men, women experience earlier and more prominent muscle strength with age.
Neurodegeneration and muscle strength decline
Reduced motor nerve performance is associated with reduced muscle performance. Neurodegeneration is characterized by changes in neuromuscular signaling and reduced muscle recruitment, which promote both atrophy. AD patients often experience muscle dependence, even in the pre -clinical stages of the disease.
Previous studies have made a connection between the Apoe ε4 genotype, a genetic risk factor for Alzheimer’s disease (AD) and a poorer motor function. Reduced muscle strength is associated with an increased risk of AD and a faster speed of cognitive decline. Although a connection between AD and Sarcopenia has been established, the mechanisms behind this muscle brain interaction remain unclear.
Insight into the longitudinal relationship between AD-related biomarkers, such as amyloid β (Aβ), phosphorylated Tau (P-Tau), glial fibrillary acidic protein (GFAP), Total Tau (T-Tau) and Neuroophilament mild chain and muscle power older adults is essential.
About the study
The current research obtained data from the Swedish National Study on aging and care in Kungsholmen (SNAC-K), an ongoing prospective study conducted in Sweden. The aim was to investigate the relationship between blood concentrations of ad-biomarkers and changes in muscle strength over time in dementia-free, community-in-people older adults.
The SNAC-K examination, conducted between 2001 and 2004, included persons aged 60 and older. Participants younger than 78 were followed every six years, while those aged 78 and older were succeeded every three years. The current study included data from basic line to the fourth follow-up. Persons with the diagnosis of dementia, AD or Parkinson’s disease, as well as those who live in institutions at the start, were excluded.
Muscle strength was assessed with the help of the hand grip strength test and the chair standard test. Blood samples were collected to measure and determine ad -biomarkers Apoe genotype. Baseline data includes personal, lifestyle and anthropometric information, such as age, gender, education, civilian state and smoking status. In particular, 99% of the research cohort consisted of white persons.
The association between basic levels of AD-related biomarkers and changes in muscle strength over time was assessed with the help of linear mixed models with random interception and slopes.
Findings
A total of 1,953 participants met the suitability criteria. Of these, 39.9% was male and 60.1% was female, with an average age of 70.2 years. About 14.5% of men and 28.0% of women showed a low strength in both tests. Reduced performance in the chair test test were observed in 25.3% of men and 35.5% of women.
Blood sample analysis revealed differences in the divisions of ad -biomarkers between genera. Participants with low muscle strength showed higher concentrations of the light chain of neurophilament, P-TAU217, P-TAU181, T-Tau and GFAP, as well as a lower ratio from Aβ42 to Aβ40.
Twelve-year-old longitudinal analyzes revealed that an increase in one-standard (SD) (SD) in P-TAU181, P-TAU217 and Neuroilament-light chain was associated with a faster decline of hand grip strength, even after correction for potential confounders. Similar trends were observed in associations between ad-linked biomarkers and hand grip strength.
The chair standard test also indicated that an increase in one-standard deviation in P-TAU181, P-TAU217, NeuroFilament Light Chain and Gfap correlated with a faster decrease in muscle performance over time. Further adjustments for the time-dependent mini-mental state exam (MMSE) score showed a reduction in the annual decrease in the limit strength. Similar findings were obtained in the primary model for incident dementia.
However, a contradictory finding has emerged in a stratified analysis Through Apoe genotype. The Biomarker P-TAU181 was associated with a faster decline of the test performance of the chair position. This association between AD-related biomarkers and a decrease in muscle strength in both tests was more pronounced with younger participants and those who were physically inactive.
Conclusions
The current study established associations between AD-linked biomarkers, in particular P-TAU217, TAU181, NeuroFilament Light chain and GFAP, and a decrease in muscle strength in older adults without dementia. It is worth noting that these associations are influenced by various factors, including age, genetic predisposition for Alzheimer’s disease, gender and systemic inflammation.
Scientists are of the opinion that the operation of AD-related biomarkers to detect persons with a high risk of sarcopenia can enable clinicians to offer them more interventions.